Home Applications 022250 Application 022250
Type NDA
Sponsor ACORDA Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 AMPYRA DALFAMPRIDINE TABLET, EXTENDED RELEASE;ORAL 10MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N022250-001 AMPYRA DALFAMPRIDINE 10MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2010-01-22
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code N022250-001 AB
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N022250-001 AMPYRA 10MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2010-01-22 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N022250-001 AMPYRA 10MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2010-01-22 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N022250-001 AMPYRA 10MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2010-01-22 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N022250-001 AMPYRA 10MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2010-01-22 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N022250-001 AMPYRA 10MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2010-01-22 a50c72e98297…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 2 · 45 observed states.
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N022250-001 8440703 2025-04-08 U-1030 Delist requested 2013-06-12 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022250-001 8354437 2026-12-22 U-1030 Delist requested 2013-02-13 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022250-001 8007826 2027-05-26 U-1030 Delist requested 2011-09-28 74a2ff9319b5…2019-12-14 00:12 UTC 2019-12 N022250-001 8440703 2025-04-08 U-1030 Delist requested 2013-06-12 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022250-001 8354437 2026-12-22 U-1030 Delist requested 2013-02-13 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022250-001 8007826 2027-05-26 U-1030 Delist requested 2011-09-28 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N022250-001 9918973 2024-12-13 U-1030 2018-04-17 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022250-001 8663685 2025-01-18 U-1030 2014-04-02 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022250-001 8440703 2025-04-08 U-1030 2013-06-12 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022250-001 8354437 2026-12-22 U-1030 2013-02-13 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022250-001 8007826 2027-05-26 U-1030 2011-09-28 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N022250-001 9918973 2024-12-13 U-1030 2018-04-17 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022250-001 8663685 2025-01-18 U-1030 2014-04-02 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022250-001 8440703 2025-04-08 U-1030 2013-06-12 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022250-001 8354437 2026-12-22 U-1030 2013-02-13 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022250-001 8007826 2027-05-26 U-1030 2011-09-28 ea99ee380514…
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 2 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 7 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0378-0509 dalfampridine dalfampridine Mylan Pharmaceuticals Inc. NDA AUTHORIZED GENERIC Current 0378-0509 dalfampridine dalfampridine Mylan Pharmaceuticals Inc. NDA AUTHORIZED GENERIC Current 10144-427 AMPYRA Dalfampridine Acorda Therapeutics, Inc. NDA Current 10144-427 AMPYRA Dalfampridine Acorda Therapeutics, Inc. NDA Current 10144-427 AMPYRA Dalfampridine Acorda Therapeutics, Inc. NDA Current 10144-427 AMPYRA Dalfampridine Acorda Therapeutics, Inc. NDA Current 10144-427 AMPYRA Dalfampridine Acorda Therapeutics, Inc. NDA Current